The HARMONY Alliance is an unparalleled medicine offensive to battle blood cancers by using Big Data analyses. One of the most important milestones that was jointly achieved in the first year of HARMONY, is the establishment of HARMONY’s Big Data platform. Public and private organizations will contribute data on most hematological cancers.
View our video, filmed during the 2nd General Assembly in October 2017, in which our HARMONY Partners explain what makes the Alliance unique and how we will ccomplish our goal of assembling, analyzing, harmonizing, and communicating comprehensive data-sets (incorporated into a big data platform) on the treatment of hematologic malignances (HM).
The use of a common data model that adheres to the FAIR (findable, accessible, interoperable, and reusable) data-sharing principles will allow analysis at an unprecedented scale to take place. This will contribute to a better understanding of these diseases, leading to the evolution of improved targeted therapies that will benefit patients. Public and private partners are bringing together their best people, data, and knowledge to solve key questions on hematological cancers. These challenges can only be met by applying the most advanced technology. Our short-term focus is three-fold: offering an ethical and legal framework on the use of medical data, analyzing the first data on the platform, and defining standard sets of outcomes.
Read more about our first year achievements by checking our 8 Work Packages.
The HARMONY Alliance is a European Network of Excellence for Big Data in Hematology, consisting of 51 partners. Our goal is unlocking valuable knowledge on hematologic malignancies (HMs). We are determined to create new treatment strategies based on big data technologies to benefit society. Our focus is three-fold: offering an ethical and legal framework on the use of medical data, analyzing the first data on the platform, and defining standard sets of outcomes. HARMONY is an IMI project, established in January 2017 for a period of 5 years.
HARMONY is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
